Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The anti-IL-17 antibody was generated at NovImmune and licensed to Genentech in July 2010. The initiation of the Phase I clinical trial triggers a milestone payment from Genentech of an undisclosed amount.
Jack Barbut, CEO, commented "With the compound entering man, NovImmune is gratified to see Genentech’s continued commitment to the anti-IL-17 program. This news creates an additional milestone as this is the fifth NovImmune therapeutic antibody to enter clinical development; a significant achievement for a small biotech company."
